Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares surge a whopping 45.6% on the day. This tremendous rally can be attributable to solid volume too with far more shares changing hands than in a normal session. This continues the most recent uptrend of the company, as the stock is now up 35.69% in the past one-month time frame.
In the last 30 days, this company did not witness any estimate revisions and the Zacks Consensus Estimate has remained unchanged over the same period. However, the recent price action is encouraging, so make sure to keep a close watch on this firm in the near future.
Avanir Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Other better-ranked players in the healthcare industry include Enanta Pharmaceuticals, Inc. (ENTA), Gilead Sciences Inc. (GILD) and TrovaGene, Inc. (TROV) all carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment